Search results

  1. Do the direct anterior, direct superior and supercapsular percutaneously assisted (SuperPATH) approaches to hip replacement improve patient-recorded outcome measures and reduce length of hospital stays, revision rates, neurological complications and surgical site infections compared with the posterior and anterolateral approaches?

    Recommendation ID NG157/11 Question Do the direct anterior, direct superior and supercapsular percutaneously assisted (SuperPATH) approaches

  2. 1.1 Evidence on the safety of electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease shows no major safety concerns. For people who are having an acute exacerbation of their chronic condition and are unable to exercise, evidence of efficacy is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit.   Find out  what standard arrangements mean on the NICE website . For people who are able to exercise, evidence on efficacy is inadequate in quality. Therefore, this procedure should only be used in the context of research. Find out  what only in research means on the NICE website .

    Recommendation ID IPG677 Question 1.1 Evidence on the safety of electrical stimulation to improve muscle strength in chronic respiratory

  3. Further research is recommended to assess the effect of test-guided preventive care (see section 5.1) on clinical outcomes (such as length of stay in hospital, mortality and need for renal replacement therapy and progression to chronic kidney disease). Research should be done in children, young people and adults, but specific considerations may be needed for children and young people when care differs from that for an adult population. Studies should investigate the effects of both positive and negative test results on clinical decisions and subsequent care.

    Recommendation ID DG39/2 Question Further research is recommended to assess the effect of test-guided preventive care (see section 5.1)

  4. Companies should specify patient populations in the NHS who could benefit from test-guided preventive care for acute kidney injury. Further research is then recommended in these populations to assess the clinical effectiveness of defined care bundles designed to prevent or reduce the effect of acute kidney injury in the NHS. Research should be done in children, young people and adults, but specific considerations may be needed for children and young people when care differs from that for an adult population (see  section 4.11 ).

    Recommendation ID DG39/1 Question Companies should specify patient populations in the NHS who could benefit from test-guided preventive

  5. Evidence on the safety of transcranial magnetic stimulation for obsessive-compulsive disorder raises no major safety concerns. However, evidence on its efficacy is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research.  Find out  what only in research means on the NICE website .

    Recommendation ID IPG676 Question Evidence on the safety of transcranial magnetic stimulation for obsessive-compulsive disorder raises

  6. Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)

    Evidence-based recommendations on treosulfan (Trecondi) with fludarabine for conditioning treatment before allogeneic haematopoietic stem cell transplant for

  7. Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease (IPG677)

    Evidence-based recommendations on electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney

  8. COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)

    The purpose of this guideline is to maximise the safety of patients who need haemopoietic stem cell transplantation and make the best use of NHS resources, while protecting staff from infection.

  9. COVID-19 rapid guideline: arranging planned care in hospitals and diagnostic services (NG179)

    The purpose of this guideline is to help healthcare professionals deliver efficient planned care while minimising the risk of COVID-19 in the context of increasing or decreasing local prevalence. It also aims to help patients make decisions about their planned care.

  10. Dudley Falls Prevention Service

    Shared learning database Organisation: Dudley Falls Prevention Service Published date: July 2019

  11. COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders (NG167)

    The purpose of this guideline is to maximise the safety of children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection. It also enables services to make the best use of NHS resources.

  12. Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)

    Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults

  13. Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)

    Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic